Key clinical point: In patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment with tiotropium/olodaterol combination therapy improves outcomes, compared with tiotropium alone.
Major finding: Patients not receiving inhaled corticosteroids who received tiotropium/olodaterol had a significantly greater improvement in trough forced expiratory volume in 1 second response by week 12 of treatment, compared with patients receiving tiotropium alone (0.054 L; P less than .0001).
Study details: Post hoc analysis of pooled data from the TONADO 1 and 2 and OTEMTO 1 and 2 trials included a total of 1,596 patients with COPD.
Disclosures: Dr. Calverley reported grants and personal fees from GlaxoSmithKline; personal fees from AstraZeneca, Recipharm, and Zambon; and personal and other fees from Boehringer Ingelheim outside the submitted work.
Calverley PM et al. CHEST 2019..